Parkinson DiseaseSLAM-PDNCT04273672

Speech, Linguistic and Acoustic Markers in Parkinson's Disease

An observational study of Parkinson Disease and Cognitive Impairment, Mild, run by University of Massachusetts, Worcester at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. Read more about this study

Who is it for?: Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for: Parkinson Disease, Cognitive Impairment, Mild, Speech
What is being tested?: Cognitive Battery, Voice, Speech and Language Analysis and Questionnaires and Clinical Assessments
Type of treatment: Lifestyle or therapy programme
How many people: 58 participants
Where: 1 siteUnited States
Study dates: 13 Jan 2020to 28 Feb 2025
Phase: Observational
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
Healthy volunteers accepted
Adult, Older adult

Study population: Adults with Parkinson's Disease and mild cognitive impairment or normal cognition as well as controls

Who may be able to join

Parkinson's Disease (or healthy control)
Disease duration ≥ 2 years
Mild cognitive impairment or normal cognition

Who cannot join

Diagnosis of dementia (MoCA <21)
Adults unable to consent
Age < 18
Pregnant women
Prisoners
Non-English speakers

Show all 12Show fewer

Any neurological disorder other than PD
Deep brain stimulator placement
Severe, unstable psychiatric disorder
Unintelligible speech due to effects of PD
Visual acuity or color vision impairment that would interfere with cognitive testing
Other voice, speech or swallowing disorders or history of surgery involving palate/nasopharynx/larynx/vocal cords

Trial locations and contacts

1 site in 1 country.

United States1 site

UMass Medical School/UMass Memorial Medical Center
Worcester, Massachusetts, 01655

Other trials in United States

About this study

Conditions: Parkinson Disease, Cognitive Impairment, Mild, Speech
Being tested: Cognitive Battery, Voice, Speech and Language Analysis, Questionnaires and Clinical Assessments, DNA Analysis
Medical subject headings: Parkinson Disease, Cognitive Dysfunction, Speech

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Cognitive BatteryDiagnostic test
Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
Voice, Speech and Language AnalysisBehavioural
Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
Questionnaires and Clinical AssessmentsBehavioural
Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
DNA AnalysisGenetic
Participants will have their blood drawn for DNA analysis.

Study groups in NCT04273672
Study group	Role	What they receive
Parkinson's Disease		Subjects with Parkinson's Disease Receives: Diagnostic Test: Cognitive Battery; Behavioral: Voice, Speech and Language Analysis; Behavioral: Questionnaires and Clinical Assessments; Genetic: DNA Analysis
Control		Subjects without Parkinson's Disease Receives: Diagnostic Test: Cognitive Battery; Behavioral: Voice, Speech and Language Analysis; Behavioral: Questionnaires and Clinical Assessments

What is being measured

The primary outcome is the main question the study is designed to answer.

Mild Cognitive Impairment
Mild cognitive impairment classified by Movement Disorders Society Task Force Level II Critieria
Measured: baseline
Mean Fundamental Frequency
These acoustic measures during spontaneous speech (picture description) were calculated using Praat
Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

13 Jan 202028 Feb 2025

First posted18 Feb 2020
Study start13 Jan 2020
Primary completion1 Sep 2023
Study completion28 Feb 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
More trials run by University of Massachusetts, WorcesterThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Cross-sectional
Enrolment: 58 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04273672
Sponsor's protocol ID: H00011523
Other IDs: 5K23DC016656
Acronym: SLAM-PD
Status last verified: Jun 2025
First submitted: 12 Feb 2020
Last updated: 10 Jun 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease

All Parkinson Disease trials

Study at a glance

From the registry record, last updated by the sponsor on 10 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Speech, Linguistic and Acoustic Markers in Parkinson's Disease
ClinicalTrials.gov ID: NCT04273672
Acronym / sponsor ID: SLAM-PD / H00011523
Conditions: Parkinson Disease, Cognitive Impairment, Mild, Speech
Study type: Observational
Recruitment status: Completed
Enrolment: 58 participants (actual)
Lead sponsor: University of Massachusetts, WorcesterUniversity, hospital or other
Collaborators: Boston University, VA Puget Sound Health Care System, National Institute on Deafness and Other Communication Disorders (NIDCD), Massachusetts Institute of Technology
Study start: 13 Jan 2020 (actual)
Primary completion: 1 Sep 2023 (actual)
Study completion: 28 Feb 2025 (actual)
First posted: 18 Feb 2020 (actual)
Results: Posted 10 Jun 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model: Cohort
Time perspective: Cross-sectional
Number of arms: 2

Arm	Type	Receives
Parkinson's Disease	–	Diagnostic Test: Cognitive Battery, Behavioral: Voice, Speech and Language Analysis, Behavioral: Questionnaires and Clinical Assessments, Genetic: DNA AnalysisSubjects with Parkinson's Disease
Control	–	Diagnostic Test: Cognitive Battery, Behavioral: Voice, Speech and Language Analysis, Behavioral: Questionnaires and Clinical AssessmentsSubjects without Parkinson's Disease

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult
Study population: Adults with Parkinson's Disease and mild cognitive impairment or normal cognition as well as controls

Key inclusion criteria (3 listed)

Parkinson's Disease (or healthy control)
Disease duration ≥ 2 years
Mild cognitive impairment or normal cognition

Key exclusion criteria (12 listed)

Diagnosis of dementia (MoCA <21)
Adults unable to consent
Age < 18
Pregnant women
Prisoners

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Cognitive BatteryParticipants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).	Diagnostic test	Control, Parkinson's Disease
Voice, Speech and Language AnalysisParticipants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.	Behavioural	Control, Parkinson's Disease
Questionnaires and Clinical AssessmentsParticipants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.	Behavioural	Control, Parkinson's Disease
DNA AnalysisParticipants will have their blood drawn for DNA analysis.	Genetic	Parkinson's Disease

Primary outcome

Mild Cognitive Impairment
Time frame: baseline
Mild cognitive impairment classified by Movement Disorders Society Task Force Level II Critieria
Mean Fundamental Frequency
Time frame: baseline
These acoustic measures during spontaneous speech (picture description) were calculated using Praat

Results and safety

Results posted to the registry on 10 Jun 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Parkinson's Disease	49	49
Control	9	9

Primary outcome: Mild Cognitive Impairment

Time frame: baseline. Count of participants. Unit: Participants

Measure	Parkinson's Disease n = 49	Control n = 9
Parkinson's disease with mild Cognitive Impairment	25	0
Parkinson's disease with normal cognition	23	9

Population analysed: The entire baseline cohort was analyzed (n=49). Per pre-specified exclusion criteria, one participant determined to have dementia (n=1) was excluded from outcome measure analysis reporting, thus the outcome measure data represents n=48 participants.

Primary outcome: Mean Fundamental Frequency

Time frame: baseline. Mean (Standard Deviation). Unit: Hz

Measure	Parkinson's Disease n = 25	Parkinson's Disease With Mild Cognitive Impairment n = 23	Controls n = 9
Value	137.7 (39.6)	142.4 (39.6)	166.4 (29.7)

Population analysed: same as enrolled

Adverse events

Time frame: This was a single visit, cross-sectional study. Adverse event data was collected during the single half-day study visit only.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Parkinson's Disease	0 of 49 (0%)	0 of 49 (0%)	0 of 49
Control	0 of 9 (0%)	0 of 9 (0%)	0 of 9

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: Undecided

Related trials for Parkinson Disease

Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Kara Smith, MD principal investigator

UMass Medical School

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Parkinson Disease and Cognitive Impairment, Mild, run by University of Massachusetts, Worcester at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Jun 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mild Cognitive Impairment (time frame: baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04273672.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2025.